are glp-1 safe Safety Check Compounded GLP-1 Safety: Supervised Weightloss
Description
The short half-life of native GLP- 1-based therapy in the circulation (approximately two minutes after intravenous administration and one to five hours after subcutaneous administration) posed a problem during its early development [9]
It also slows the emptying of the stomach, enhancing the sensation of fullness after meals
Both treatments were safe with benign safety profiles
GLP-1RAs have transformed the treatment landscape for diabetes and obesity, making them promising candidates for MASLD
Manufactured by Novo Nordisk at a list price approaching $1,000 per month, Wegovy was also the drug that most patients associated with the GLP-1 weight loss revolution
Most participants reported that nausea was most pronounced during dose escalation periods and tended to diminish with continued use at stable doses
